University of Texas's MD Anderson Cancer Center: Poziotinib Is Active in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer With Efficacy Highly Dependent on Insertion Location
July 12, 2022
July 12, 2022
HOUSTON, Texas, July 12 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 11, 2022:
* * *
Study suggests a new level of precision medicine is required for some lung cancers
* * *
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer . . .
* * *
Study suggests a new level of precision medicine is required for some lung cancers
* * *
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer . . .